Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Safety of multikinase inhibitors in metastatic renal cell carcinoma and indirect treatment comparisons.

Catalá-López F.

Eur J Cancer. 2013 Mar;49(4):984-5. doi: 10.1016/j.ejca.2012.10.011. Epub 2012 Nov 6. No abstract available.

PMID:
23140823
2.

The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb S, Shamash J, Stockdale A, Lim L, Nathan P, Chowdury S.

Eur J Cancer. 2013 Mar;49(4):986-7. doi: 10.1016/j.ejca.2012.10.010. Epub 2012 Nov 5. No abstract available.

PMID:
23138000
3.

PISCES: a horoscope for first-line targeted therapy of metastatic renal cell carcinoma.

Sun M, Larcher A, Schiffmann J, Karakiewicz PI.

J Clin Oncol. 2014 Nov 20;32(33):3783. doi: 10.1200/JCO.2014.57.4673. Epub 2014 Sep 29. No abstract available.

4.

Benefits of pazopanib over sunitinib for renal cell carcinoma.

Granovetter M.

Lancet Oncol. 2016 Mar;17(3):e93. doi: 10.1016/S1470-2045(16)00081-4. Epub 2016 Feb 5. No abstract available.

PMID:
26853821
5.

Kidney cancer: in crossover study, patients and physicians prefer pazopanib.

Phillips R.

Nat Rev Urol. 2014 May;11(5):246. doi: 10.1038/nrurol.2014.87. Epub 2014 Apr 15. No abstract available.

PMID:
24731995
6.

PISCES trial: the end does not always justify the means.

Barni S, Petrelli F.

J Clin Oncol. 2014 Nov 20;32(33):3782-3. doi: 10.1200/JCO.2014.56.8832. Epub 2014 Sep 29. No abstract available.

7.

How to interpret patient preferences in selecting the best drug: are the current measurements up to the job?

Garnick MB.

J Clin Oncol. 2014 May 10;32(14):1392-3. doi: 10.1200/JCO.2014.55.1911. Epub 2014 Mar 31. No abstract available.

8.

An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb SJ, Shamash J, Stockdale A, Rashid S, Nathan P, Chowdury S.

Eur J Cancer. 2012 Nov;48(17):3171-6. doi: 10.1016/j.ejca.2012.05.022. Epub 2012 Jul 4.

PMID:
22766517
9.

Reply to S. Barni et Al and M. Sun et Al.

Garnick MB.

J Clin Oncol. 2014 Nov 20;32(33):3785. doi: 10.1200/JCO.2014.57.9227. Epub 2014 Sep 29. No abstract available.

10.

Reply to S. Barni et Al and M. Sun et Al.

Escudier B, Porta C, Powles T, Eisen T, Sternberg CN, Mehmud F, Cella D.

J Clin Oncol. 2014 Nov 20;32(33):3783-4. doi: 10.1200/JCO.2014.57.9219. Epub 2014 Sep 29. No abstract available.

11.

Pazopanib outscores sunitinib on tolerability.

[No authors listed]

Cancer Discov. 2014 Jan;4(1):OF8. doi: 10.1158/2159-8290.CD-NB2013-131. Epub 2013 Sep 19.

12.

Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.

Park S, Lee J, Park SH, Park JO, Kang WK, Park YS, Cho JH, Lim HY.

Chemotherapy. 2010;56(6):485-91. doi: 10.1159/000321033. Epub 2010 Nov 24.

PMID:
21099221
13.

Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.

Vickers MM, Heng DY, Hemmelgarn B, Eigl BJ.

Clin Genitourin Cancer. 2009 Oct;7(3):E104-6. doi: 10.3816/CGC.2009.n.035.

PMID:
19815480
14.

Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.

Leung HW, Chan AL.

Clin Ther. 2011 Jun;33(6):708-16. doi: 10.1016/j.clinthera.2011.05.003.

PMID:
21704235
15.

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.

O'Donnell PH.

BJU Int. 2011 Oct;108(8):1284-5. doi: 10.1111/j.1464-410X.2011.10179.x. Epub 2011 Mar 18. No abstract available.

16.

Hypertension as a predictive factor of Sunitinib activity.

Rixe O, Billemont B, Izzedine H.

Ann Oncol. 2007 Jun;18(6):1117. No abstract available.

17.

Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

van den Meiracker AH, Danser AH, Sleijfer S, Kappers MH.

J Natl Cancer Inst. 2011 Oct 19;103(20):1557; author reply 1558. doi: 10.1093/jnci/djr328. Epub 2011 Aug 23. No abstract available.

18.

Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.

Al Enazi MM, Kadry R, Mitwali H.

J Am Acad Dermatol. 2009 Nov;61(5):905-6. doi: 10.1016/j.jaad.2008.12.030. No abstract available.

PMID:
19836653
19.

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.

Lee JL, Park I, Park K, Park S, Ahn Y, Ahn JH, Kim TW, Ahn S, Song C, Hong JH, Kim CS, Ahn H.

J Cancer Res Clin Oncol. 2012 Apr;138(4):687-93. doi: 10.1007/s00432-012-1148-8. Epub 2012 Jan 12.

PMID:
22237457
20.

Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.

Huang J, Wang T, Huang Y.

Med Oncol. 2013 Mar;30(1):436. doi: 10.1007/s12032-012-0436-0. Epub 2013 Jan 3. No abstract available.

PMID:
23283650
Items per page

Supplemental Content

Write to the Help Desk